BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1245 related articles for article (PubMed ID: 34358692)

  • 21. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guillain-Barré syndrome and COVID-19 vaccines: focus on adenoviral vectors.
    Rzymski P
    Front Immunol; 2023; 14():1183258. PubMed ID: 37180147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of COVID-19 vaccine type on Guillain-Barré syndrome: Two cases and a literature review.
    Lee HY; Lien WC
    Hum Vaccin Immunother; 2023 Dec; 19(1):2171231. PubMed ID: 36919452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guillain-Barrè syndrome following COVID-19 vaccine mRNA-1273: a case report.
    Masuccio FG; Comi C; Solaro C
    Acta Neurol Belg; 2022 Oct; 122(5):1369-1371. PubMed ID: 34767184
    [No Abstract]   [Full Text] [Related]  

  • 25. A Clinical Case of COVID-19 Vaccine-Associated Guillain-Barré Syndrome.
    Hilts A; Schreiber A; Singh A
    Am J Case Rep; 2022 Aug; 23():e936896. PubMed ID: 35945825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
    Walker JL; Schultze A; Tazare J; Tamborska A; Singh B; Donegan K; Stowe J; Morton CE; Hulme WJ; Curtis HJ; Williamson EJ; Mehrkar A; Eggo RM; Rentsch CT; Mathur R; Bacon S; Walker AJ; Davy S; Evans D; Inglesby P; Hickman G; MacKenna B; Tomlinson L; Ca Green A; Fisher L; Cockburn J; Parry J; Hester F; Harper S; Bates C; Evans SJ; Solomon T; Andrews NJ; Douglas IJ; Goldacre B; Smeeth L; McDonald HI
    Vaccine; 2022 Jul; 40(32):4479-4487. PubMed ID: 35715350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case Report: Post-COVID-19 Vaccine Recurrence of Guillain-Barré Syndrome Following an Antecedent Parainfectious COVID-19-Related GBS.
    Bellucci M; Germano F; Grisanti S; Castellano C; Tazza F; Mobilia EM; Visigalli D; Novi G; Massa F; Rossi S; Durando P; Cabona C; Schenone A; Franciotta D; Benedetti L
    Front Immunol; 2022; 13():894872. PubMed ID: 35924236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guillain-Barre syndrome following COVID-19 vaccines: A scoping review.
    Lahoz Fernandez PE; Miranda Pereira J; Fonseca Risso I; Baleeiro Rodrigues Silva P; Freitas Barboza IC; Vieira Silveira CG; Diogo Silva G; Marzorati Kuntz Puglia P; Genaro Mutarelli E
    Acta Neurol Scand; 2022 Apr; 145(4):393-398. PubMed ID: 34967005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature.
    Min YG; Ju W; Ha YE; Ban JJ; Lee SA; Sung JJ; Shin JY
    J Neuroimmunol; 2021 Oct; 359():577691. PubMed ID: 34416410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guillain-Barré syndrome in an era of global infections and 21st century vaccination.
    Lunn MP
    Curr Opin Neurol; 2022 Oct; 35(5):571-578. PubMed ID: 36069416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Case Report of Guillain-Barré Syndrome In Association with SARS-CoV-2 Vaccination in Malaysia.
    Sii HL; Ng SH; Wong VF; Law WC
    Acta Neurol Taiwan; 2023 Dec; 32(4)():207-211. PubMed ID: 37723913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guillain-Barré syndrome after COVID-19 vaccination.
    McKean N; Chircop C
    BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34330729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study.
    García-Grimshaw M; Ceballos-Liceaga SE; Hernández-Vanegas LE; Núñez I; Hernández-Valdivia N; Carrillo-García DA; Michel-Chávez A; Galnares-Olalde JA; Carbajal-Sandoval G; Del Mar Saniger-Alba M; Carrillo-Mezo RA; Fragoso-Saavedra S; Espino-Ojeda A; Blaisdell-Vidal C; Mosqueda-Gómez JL; Sierra-Madero J; Pérez-Padilla R; Alomía-Zegarra JL; López-Gatell H; Díaz-Ortega JL; Reyes-Terán G; Arauz A; Valdés-Ferrer SI
    Clin Immunol; 2021 Aug; 229():108786. PubMed ID: 34147649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?
    Oo WM; Giri P; de Souza A
    J Neuroimmunol; 2021 Nov; 360():577719. PubMed ID: 34560365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 vaccine-related Guillain-Barré syndrome in the Liguria region of Italy: A multicenter case series.
    Germano F; Bellucci M; Grisanti S; Beronio A; Grazzini M; Coco E; Tassinari T; Della Cava F; De Michelis C; Baldi O; Sivori G; Murialdo A; Cabona C; Durando P; Uccelli A; Schenone A; Franciotta D; Benedetti L
    J Neurol Sci; 2022 Sep; 440():120330. PubMed ID: 35802961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guillain-Barre syndrome following COVID-19 vaccines: A review of literature.
    Yu M; Nie S; Qiao Y; Ma Y
    Front Immunol; 2023; 14():1078197. PubMed ID: 36875094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guillain-Barré syndrome in association with COVID-19 vaccination: a systematic review.
    Abolmaali M; Rezania F; Behnagh AK; Hamidabad NM; Gorji A; Mirzaasgari Z
    Immunol Res; 2022 Dec; 70(6):752-764. PubMed ID: 36098903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No significant increase in Guillain-Barré syndrome after COVID-19 vaccination in adults: A vaccine adverse event reporting system study.
    Jaffry M; Mostafa F; Mandava K; Rosario S; Jagarlamudi Y; Jaffry K; Kornitzer J; Jedidi K; Khan H; Souayah N
    Vaccine; 2022 Sep; 40(40):5791-5797. PubMed ID: 36055875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2.
    Leung C
    Hum Vaccin Immunother; 2021 Sep; 17(9):2957-2958. PubMed ID: 34032555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.